Nephro Care India Limited (**NCIL**) is a specialized healthcare provider headquartered in Kolkata, dedicated to the comprehensive management of renal (kidney) diseases. Founded in **2014** by renowned nephrologist **Dr. Pratim Sengupta**, the company has evolved from a single clinic into a multi-facility healthcare ecosystem. NCIL successfully listed on the **NSE Emerge** platform in **July 2024**, raising **₹41.26 crore** to fund its transition into a multispecialty hospital operator and technology innovator. --- ### **The Hub-and-Spoke Operational Model** NCIL utilizes a capital-efficient, **asset-light hub-and-spoke model** designed to bridge the massive demand-supply gap in Indian renal care, where **2.2 lakh** new End-Stage Renal Disease (**ESRD**) patients are added annually. * **The Central Hub (Vivacity Multispecialty Hospital):** Located in **Madhyamgram, Kolkata**, this flagship **100-bed** facility (expandable to **150-250 beds**) serves as the core for advanced surgical and tertiary care. * **Spoke Clinics:** A growing network of satellite facilities providing local access to dialysis and outpatient services. Current locations include **Salt Lake**, **Chandannagar**, **Shyambazar**, and **Alipurduar**. * **Strategic Partnerships:** The company extends its reach through **Public-Private Partnerships (PPP)**, such as the center at **Tapan Sinha Memorial Hospital (Metro Railway Kolkata)**, and tie-ups with private entities like **Tulip Hospital** and **Synergy Global Care Hospital**. --- ### **Revenue Streams and Financial Performance** The company’s revenue mix is diversifying as it transitions from outpatient clinics to full-scale hospital operations. | Segment | Revenue Share (Aug 2025) | Description | | :--- | :--- | :--- | | **OPD Services** | **52%** | Diagnostics, physical exams, and professional consultations. | | **Pharmacy Sales** | **25%** | Sale of pharmaceutical products; NCIL is also a stockist for **Cadila Healthcare**. | | **IPD Services** | **23%** | Critical care, surgeries, and renal transplants. | **Key Financial Metrics:** * **Revenue Growth:** Standalone revenue for **H1 FY26** reached **₹39.33 crore**, a **38.76%** increase over **H2 FY25**. * **Profitability:** **FY25 PAT** stood at **₹3.64 crore**. While revenue grew, margins were temporarily compressed (EBITDA margin of **16.08%** in FY25 vs **25.10%** in FY24) due to a **251.38%** surge in employee benefit expenses to staff the new flagship hospital. * **Capital Allocation:** **₹26.17 crore** of IPO proceeds were directed toward the **Vivacity Hospital** project. The company maintains a policy of reinvesting profits into general reserves to fuel expansion. --- ### **Clinical Excellence and Specialized Units** NCIL provides a **360-degree** healthcare framework that combines high-end surgical intervention with holistic wellness. * **Renal Transplant Unit:** Following government approval, the company performed its **first kidney transplant** in **May 2025**. It targets **25+ transplants** by the end of **FY26**. * **Cardiothoracic & Vascular Surgery (CTVS):** A specialized unit addressing the high incidence of cardiovascular complications in renal patients, capable of bypass and minimally invasive surgeries. * **Critical Care:** The flagship hospital features a **30-bed Critical Care Unit** (ICU, HDU, RTU, NICU) with **AI-powered smart operation theatres**. * **Holistic Programs:** * **Mukti:** Integrates modern medicine with **yoga and nutrition**; has reached **8,000+ patients**. * **360-Series:** Targeted management for Diabetes (**Diaguard 360**), Obesity (**ReShape 360**), and Renal support (**Renoguard 360**). --- ### **Technological Disruption and R&D** A core pillar of NCIL’s strategy is reducing the cost of care through indigenous innovation and digital integration. * **Indigenous Dialysis Machine:** In collaboration with **NIT Silchar**, NCIL is developing a prototype **Smart Haemodialysis Machine**. The target is to reduce the machine cost from the current market rate of **₹7.5–8 lakh** to approximately **₹2 lakh** (a **70-75% reduction**). * **AI-Enabled Diagnostics:** Deployment of the **Logiq Totus** ultrasound system, featuring voice control and AI-based scan guidance. * **Digital Infrastructure:** Centralized **Electronic Health Records (EHR)** and remotely monitored dialysis systems to ensure data-driven patient management. --- ### **Strategic Roadmap: 2026 and Beyond** NCIL is aggressively scaling its footprint to become a national player in renal care. * **Network Expansion:** Target of **22 clinics by March 2026**. * **Geographic Diversification:** Expanding beyond West Bengal into **Odisha**, **Jharkhand**, and **Maharashtra** (with a new **5,000 sq. ft. hub in Bandra, Mumbai**). * **International Ambitions:** Exploring a **Joint Venture** to enter the **Bangladesh** healthcare market. * **Franchisee Model:** Developing a model to license its wellness and "Mukti" frameworks to other healthcare chains. * **Rural Outreach:** Establishing **15 Information Centers** in rural areas for early detection and patient education. --- ### **Risk Profile and Mitigation** Investors should note the following systemic and operational risks: | Risk Category | Details | Mitigation Strategy | | :--- | :--- | :--- | | **Regulatory** | Inconsistent state adoption of transplant laws and residency constraints. | Active compliance monitoring and alignment with the **2023 National Organ Donation Policy**. | | **Operational** | High employee costs and difficulty in sourcing compatible organ donors. | Transitioning to a **profit-sharing model** with local nephrologists; training **Dialysis Technicians** in-house. | | **Financial** | Rising healthcare inflation (projected **13%** in 2025) and forex volatility. | Stringent **cost-control measures** and empanelment with programs like **Swasthya Sathi** (coverage up to **₹5 lakh**). | | **Market** | Competition from large hospital chains and diagnostic centers. | Focus on niche **specialized renal care** and proprietary low-cost technology. | ### **Leadership Team** * **Dr. Pratim Sengupta (MD & CEO):** Pioneer nephrologist with over **1,000 transplants** performed. * **Tapas Saha (CFO):** Overseeing capital allocation and treasury management. * **Arnab Majumder (COO):** Leading operational scaling and digital integration.